Close this search box.

CAR-T Cancer Drugs Get Nod of Approval from ICER

Innovative but expensive CAR-T therapies for cancer are worth their price, announced the Institute for Clinical and Economic Review recently.  The organization is the self-appointed arbiter of drug costs.  But its decision was hardly news for those in the cancer community.